

Improve your upstream manufacturing with Recombinant Insulin and TrypsiNNex®

Top 5 challenges in upstream Biomanufacturing



Risk of contamination with biological impurities from animal-derived materials jeopardizes product safety.



Process variability affects reproducibility, production efficiency, and regulatory compliance.



Process efficiency ensures you are cost-effective and adaptable to changing market demands.



Supply chain delays disrupt production and waste valuable time and resources.



Need of high-quality raw materials to ensure the safety of your biopharmaceuticals.

How Recombinant Insulin and TrypsiNNex® address these challenges



Fully animal-free and recombinant Insulin and TrypsiNNex® minimize contamination risk **and reduce** costly viral testing.



Recombinant Insulin and TrypsiNNex® show **consistent high quality** batch after batch for predictable performance and reproducible results.



Recombinant Insulin and TrypsiNNex® **support cell viability and increase viral titers**, streamlining production with a robust and efficient process.



Novo Nordisk Pharmatech's secure global supply chain ensures **dependable TrypsiNNex® and Recombinant Insulin** access for uninterrupted production.



Recombinant Insulin and TrypsiNNex® **are produced under GMP and packed in compliance with ISO 9001.**

Discover more...



TrypsiNNex®:
Efficient virus propagation
and cell-dissociation



Recombinant Insulin:
Improved cell proliferation
and process productivity